6533b862fe1ef96bd12c7707

RESEARCH PRODUCT

Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients

Gaetano Restivo PantaloneMarcello CapraRosario Di MaggioLorella PitroloAngela VitranoAngela CiancioMichele RizzoPaolo RiganoAurelio MaggioGiuseppe D'ascolaGaetano LucaniaPaolo CianciulliLuciano ProssomaritiGiuseppina CalvarusoLiana CucciaFrancesco GagliardottoCalogera GerardiAldo FilosaSaveria CampisiVincenzo Caruso

subject

AdultMalemedicine.medical_specialtyTime FactorsPyridonesHeart VentriclesThalassemiaDeferoxamineIron Chelating AgentsModels BiologicalDrug Administration Schedulechemistry.chemical_compoundInternal medicineHumansMedicineLeft ventricular ejectionDeferiproneIn patientRetrospective StudiesUltrasonographyEjection fractionbusiness.industrybeta-ThalassemiaStroke VolumeHematologymedicine.diseasehumanitieschemistryCardiologyDrug Therapy CombinationFemaleThalassemia major Left ventricular ejection fraction Deferiprone sequential deferiprone-deferoxamine Echocardiography ChelationbusinessDeferiprone

description

A multicenter randomized open-label long-term sequential deferiprone–deferoxamine (DFP-DFO) versus DFP alone trial (sequential DFP-DFO) performed in patients with thalassemia major (TM) was retrospectively reanalyzed to assess the variation in the left ventricular ejection fraction (LVEF) [1].

yearjournalcountryeditionlanguage
2012-05-24American Journal of Hematology
https://doi.org/10.1002/ajh.23219